Spectrum's Rolontis hits another setback as FDA faces COVID-19 plant inspection backlog

The COVID-19 pandemic has disrupted another biopharma company's plan to launch a new medicine. This time, it's Spectrum Pharmaceuticals' neutropenia candidate Rolontis—and the delay stings particularly for Spectrum after its decision to sell marketed meds and focus on R&D.